 G-BA assessed Glybera ® , but could not conclude on its benefits due to limited data submitted by manufacturer.
[9]  In June 2015, HAS announced that Glybera does not have a significant budget impact therefore it will not have to go through medico-economic assessment. [3] MACI ®
• Since 1998, before the ATMPs' regulation, MACI ® was available in several European countries : Germany, Italy, Spain, UK.
• In 2013, it was approved in the EU for the repair of symptomatic, full-thickness cartilage defects of the knee. Its MA was suspended in December 2014 due to the closure of EU manufacturing site. [2] • MACI ® is under evaluation in the UK and Germany:
 G-BA extended the suspension of the review and decisions on quality assurance of MACI ® until 31 December 2019 waiting for additional data on long term safety.
[9]  MACI ® will be assessed by NICE with Chondrocelect ® as mentioned in the block scoping report for autologous chondrocytes implantation. [4] Provenge ®
• Approved in 2013 for asymptomatic or minimally symptomatic metastatic (nonvisceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. Its MA was withdrawn in May 2015 in EU due to the bankruptcy of the manufacturer Dendreon. [2] • It is not reimbursed in any of the big 5 EU countries:
 It is not recommended in the UK. NICE concluded that Provenge ® did not demonstrate either additional benefit or cost-effectiveness compared to best supportive care.
[4]  IQWiG/G-BA concluded "non-quantifiable" added benefit. [9] Holoclar ®
• Approved in February 2015 [2] in the EU for moderate to severe limbal stem cell deficiency, it has not yet been assessed.
DISCUSSION
• Our results show the difficulties preventing these therapies from reaching the market; Chondrocelect ® the first ATMP, approved six years ago, is until now, only reimbursed in some countries.
• In addition, these therapies expected to be very expensive, are put under scrutiny from payers and HTA bodies which usually postpone their final decisions due to limited data.
• Proving the added value of ATMPs and their efficacy is the most important challenge facing the manufacturers, as it has to be taken into consideration during the early stages of development. • However, adaptive pathways for licensing and coverage of drugs might be a relevant approach for these medicines to reduce uncertainty through real-world data collection post-launch. 
Market Access of ATMPs: Overview and Expected Challenges

BACKGROUND
• Advanced Therapy Medicinal Products (ATMPs) constitute a class of innovative and regenerative therapies.
• This class encompasses Gene Therapy Medicinal Products (GTMPs), somatic Cell Therapy Medicinal Products (sCTMPs), Tissue Engineered Products (TEPs), and combined products (tissue or cell associated with a device). [1] • As of October 2015, only 5 ATMPs have been granted a Marketing Authorisation (MA) in the European Union (EU): [2]  Chondrocelect ® , Glybera ® , MACI ® , Provenge ® , and Holoclar ® OBJECTIVES
• The aim of this study was to review ATMPs' assessments by EU HTA bodies in the big 5 EU countries: France, Germany, Italy, Spain, and the United Kingdom (UK).
METHODS
• The EU's big 5 HTA bodies websites were searched for their decisions on ATMPs: • Grey literature was also searched for further details.
RESULTS
Chondrocelect ®
• First ATMP approved in the EU in 2009 for the repair of single symptomatic cartilage defects of the femoral condyle of the knee. [2] .
• Chondrocelect ® is reimbursed in Spain, not recommended in France, and under evaluation in the UK: (Figure 1) 
